Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples.
Acute exacerbation
Chronic obstructive pulmonary disease
Droplet digital RT-PCR
Moraxella catarrhalis
Non-typeable Haemophilus influenzae
RNA expression
Sputum
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
received:
19
01
2022
accepted:
31
08
2023
medline:
2
11
2023
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by airflow-limiting inflammation and mucus production. Acute exacerbations are a major cause of COPD-related morbidity and mortality and are mostly associated with bacterial or viral infections. A vaccine targeting non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat), the main bacteria associated with exacerbations, was tested in a Phase 2 trial. We assessed "ex-vivo" expression of vaccine candidate and housekeeping genes pd, pe, pilA, gapA, ompP6 of NTHi, and uspA2, parE, polA of Mcat in sputum samples of COPD patients and determined whether expression of the vaccine candidate genes pd, pe, pilA (NTHi) and uspA2 (Mcat) differed between stable and exacerbation samples. A single-centre, prospective, observational cohort study was conducted where 123 COPD patients were seen on enrolment, followed monthly for 2 years, and reviewed after onset of acute exacerbations. We selected 69 patients with sputum samples positive for NTHi or Mcat by PCR during at least one stable and one exacerbation visit. mRNA was isolated from the sputum, and expression of NTHi and Mcat genes was analysed with RT-PCR. Statistical analyses compared mRNA concentrations between stable and exacerbation samples and in relationship to COPD severity and exacerbation frequency. The vaccine candidate genes were variably expressed in sputum samples, suggesting they are expressed in the lung. Absolute and relative expression of all NTHi vaccine candidate genes and Mcat uspA2 were similar between exacerbation and stable samples. Expression of pd and pilA was slightly associated with the number of exacerbations in the year before enrolment, and uspA2 with the disease severity status at enrolment. The NTHi-Mcat vaccine candidate genes were expressed in sputum samples, and each gene had a specific level of expression. No statistically significant differences in gene expression were detectable between stable and exacerbation samples. However, the history of COPD exacerbations was slightly associated with the expression of pd, pilA and uspA2. Trial registration NCT01360398 ( https://www. gov ).
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by airflow-limiting inflammation and mucus production. Acute exacerbations are a major cause of COPD-related morbidity and mortality and are mostly associated with bacterial or viral infections. A vaccine targeting non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat), the main bacteria associated with exacerbations, was tested in a Phase 2 trial. We assessed "ex-vivo" expression of vaccine candidate and housekeeping genes pd, pe, pilA, gapA, ompP6 of NTHi, and uspA2, parE, polA of Mcat in sputum samples of COPD patients and determined whether expression of the vaccine candidate genes pd, pe, pilA (NTHi) and uspA2 (Mcat) differed between stable and exacerbation samples.
METHODS
METHODS
A single-centre, prospective, observational cohort study was conducted where 123 COPD patients were seen on enrolment, followed monthly for 2 years, and reviewed after onset of acute exacerbations. We selected 69 patients with sputum samples positive for NTHi or Mcat by PCR during at least one stable and one exacerbation visit. mRNA was isolated from the sputum, and expression of NTHi and Mcat genes was analysed with RT-PCR. Statistical analyses compared mRNA concentrations between stable and exacerbation samples and in relationship to COPD severity and exacerbation frequency.
RESULTS
RESULTS
The vaccine candidate genes were variably expressed in sputum samples, suggesting they are expressed in the lung. Absolute and relative expression of all NTHi vaccine candidate genes and Mcat uspA2 were similar between exacerbation and stable samples. Expression of pd and pilA was slightly associated with the number of exacerbations in the year before enrolment, and uspA2 with the disease severity status at enrolment.
CONCLUSIONS
CONCLUSIONS
The NTHi-Mcat vaccine candidate genes were expressed in sputum samples, and each gene had a specific level of expression. No statistically significant differences in gene expression were detectable between stable and exacerbation samples. However, the history of COPD exacerbations was slightly associated with the expression of pd, pilA and uspA2. Trial registration NCT01360398 ( https://www.
CLINICALTRIALS
RESULTS
gov ).
Identifiants
pubmed: 37798723
doi: 10.1186/s12931-023-02525-z
pii: 10.1186/s12931-023-02525-z
pmc: PMC10552247
doi:
Substances chimiques
Haemophilus Vaccines
0
RNA, Messenger
0
RNA
63231-63-0
Banques de données
ClinicalTrials.gov
['NCT01360398']
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
243Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Eur Respir J. 2013 Sep;42(3):559-63
pubmed: 24000245
Health Qual Life Outcomes. 2009 Jul 22;7:69
pubmed: 19624834
J Clin Microbiol. 2014 Dec;52(12):4217-23
pubmed: 25253795
Thorax. 2004 May;59(5):387-95
pubmed: 15115864
Thorax. 2017 Oct;72(10):919-927
pubmed: 28432209
Vaccine. 2019 May 21;37(23):3113-3122
pubmed: 31029515
Eur Respir J. 2019 Dec 4;54(6):
pubmed: 31601710
Am J Respir Crit Care Med. 2008 Dec 1;178(11):1139-47
pubmed: 18723437
Thorax. 2018 May;73(5):422-430
pubmed: 29386298
Eur Respir J. 2014 Jun;43(6):1787-90
pubmed: 24311775
BMJ Open. 2014 Mar 07;4(3):e004546
pubmed: 24607562
N Engl J Med. 2008 Nov 27;359(22):2355-65
pubmed: 19038881
Int J Chron Obstruct Pulmon Dis. 2015 Dec 01;10:2581-91
pubmed: 26664106
Lancet. 2012 Apr 7;379(9823):1341-51
pubmed: 22314182
Thorax. 2002 Oct;57(10):847-52
pubmed: 12324669
Eur Respir J. 2016 Apr;47(4):1082-92
pubmed: 26917613
Respir Res. 2021 Feb 24;22(1):67
pubmed: 33627095
PLoS One. 2014 Mar 21;9(3):e93031
pubmed: 24658132